In a recent study published in the Journal of Clinical Medicine , a group of researchers described the clinical characteristics of patients with type 2 diabetes (T2D) initiating oral semaglutide and assessed its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice. Study: Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment . Image Credit: luchschenF/Shutterstock.
com Semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available in an oral formulation. Its efficacy in glycemic control, BW reduction, and safety have been consistently demonstrated in the Peptide Innovation for Early Diabetes Treatment (PIONEER) trials program, which includes ten randomized controlled trials involving 9,543 subjects with T2D. The PIONEER program tested oral semaglutide across different stages of diabetes and various background treatments.
Approved by the Food and Drug Administration (FDA) in 2019 and the European Medicines Agency (EMA) in 2020, it has been available in Italy since September 2021. Further research is needed to evaluate the long-term cardiovascular outcomes and real-world effectiveness of oral semaglutide in diverse patient populations. The present study was conducted in two Italian university-based diabetes centers using data from the Metaclinic/Medical Technology and Diagnostic Application.
